BR112023016445A2 - Anticorpos anti-cd30l e seus usos - Google Patents

Anticorpos anti-cd30l e seus usos

Info

Publication number
BR112023016445A2
BR112023016445A2 BR112023016445A BR112023016445A BR112023016445A2 BR 112023016445 A2 BR112023016445 A2 BR 112023016445A2 BR 112023016445 A BR112023016445 A BR 112023016445A BR 112023016445 A BR112023016445 A BR 112023016445A BR 112023016445 A2 BR112023016445 A2 BR 112023016445A2
Authority
BR
Brazil
Prior art keywords
cd30l antibodies
cd30l
antibodies
disease
ibd
Prior art date
Application number
BR112023016445A
Other languages
English (en)
Inventor
Burton Barnett
Jessie-Farah Fecteau
Johan Fransson
Mark Renshaw
Olivier Laurent
Original Assignee
Dr Falk Pharma Gmbh
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Falk Pharma Gmbh, Prometheus Biosciences Inc filed Critical Dr Falk Pharma Gmbh
Publication of BR112023016445A2 publication Critical patent/BR112023016445A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos anti-cd30l e seus usos. são descritos, neste documento, anticorpos anti-cd30l e composições farmacêuticas para o tratamento de doenças e distúrbios autoimunes, tais como doença inflamatória intestinal (ibd), incluindo doença de crohn (cd) e colite ulcerativa (uc).
BR112023016445A 2021-02-17 2022-02-16 Anticorpos anti-cd30l e seus usos BR112023016445A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163150373P 2021-02-17 2021-02-17
PCT/US2022/016565 WO2022177963A1 (en) 2021-02-17 2022-02-16 Anti-cd30l antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112023016445A2 true BR112023016445A2 (pt) 2023-12-12

Family

ID=82931610

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023016445A BR112023016445A2 (pt) 2021-02-17 2022-02-16 Anticorpos anti-cd30l e seus usos

Country Status (18)

Country Link
US (2) US11866505B2 (pt)
EP (1) EP4294840A1 (pt)
JP (1) JP2024509746A (pt)
KR (1) KR20230157356A (pt)
CN (2) CN117255802A (pt)
AR (1) AR124895A1 (pt)
AU (1) AU2022224561A1 (pt)
BR (1) BR112023016445A2 (pt)
CA (1) CA3208060A1 (pt)
CL (1) CL2023002393A1 (pt)
CO (1) CO2023011962A2 (pt)
CR (1) CR20230445A (pt)
EC (1) ECSP23070234A (pt)
IL (1) IL305146A (pt)
MX (1) MX2023009621A (pt)
PE (1) PE20231680A1 (pt)
TW (1) TW202302637A (pt)
WO (1) WO2022177963A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305146A (en) 2021-02-17 2023-10-01 Prometheus Biosciences Inc Anti-CD30L antibodies and their uses
WO2024026271A1 (en) * 2022-07-25 2024-02-01 Prometheus Biosciences, Inc. Anti-cd30l antibodies, formulations therefor, and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
EP0615451B1 (en) * 1992-05-26 2005-12-07 Immunex Corporation Novel cytokine that binds cd30
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
ATE458007T1 (de) 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1667730B1 (en) 2003-08-20 2013-06-26 University of Miami Compositions and methods for treating inflammatory lung disease
MX352274B (es) * 2011-10-21 2017-11-16 Nestec Sa Metodos para mejorar el diagnostico de enfermedad inflamatoria intestinal.
IL307989A (en) * 2012-04-27 2023-12-01 Novo Nordisk As Human CD30 ligand antigen-binding proteins
WO2017058944A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
WO2017127537A1 (en) 2016-01-19 2017-07-27 Thomas Blumenthal Down syndrome biomarkers and uses thereof
WO2019212899A1 (en) * 2018-04-30 2019-11-07 Cedars-Sinai Medical Center Methods and systems for selection and treatment of patients with inflammatory diseases
WO2020096046A1 (ja) 2018-11-09 2020-05-14 国立大学法人大阪大学 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン
IL305146A (en) 2021-02-17 2023-10-01 Prometheus Biosciences Inc Anti-CD30L antibodies and their uses

Also Published As

Publication number Publication date
US11866505B2 (en) 2024-01-09
EP4294840A1 (en) 2023-12-27
KR20230157356A (ko) 2023-11-16
PE20231680A1 (es) 2023-10-19
JP2024509746A (ja) 2024-03-05
CR20230445A (es) 2023-11-14
WO2022177963A1 (en) 2022-08-25
CL2023002393A1 (es) 2024-03-22
IL305146A (en) 2023-10-01
AR124895A1 (es) 2023-05-17
MX2023009621A (es) 2023-10-31
ECSP23070234A (es) 2023-10-31
TW202302637A (zh) 2023-01-16
CN117255802A (zh) 2023-12-19
CA3208060A1 (en) 2022-08-25
US20240092923A1 (en) 2024-03-21
US20230060624A1 (en) 2023-03-02
AU2022224561A9 (en) 2023-10-05
AU2022224561A1 (en) 2023-09-28
CN118047872A (zh) 2024-05-17
CO2023011962A2 (es) 2023-09-29

Similar Documents

Publication Publication Date Title
BR112023016445A2 (pt) Anticorpos anti-cd30l e seus usos
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
MY191324A (en) Neutralizing anti-tl1a monoclonal antibodies
BR112017024264A2 (pt) ?composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para suaadministração?
EA202091508A1 (ru) 6-азаиндольные соединения
EA201792047A1 (ru) Новые соединения
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112012010759A2 (pt) composições e métodos de tratamento da colite e de outras doenças instestinais
BR112018011228A2 (pt) tratamentos de combinação e seus usos e métodos
CR20120562A (es) Compuestos heterocíclicos y sus usos
CL2018000622A1 (es) Acetamida tienodiazepinas de triazol y sus usos relacionados.
CO2021002670A2 (es) Inhibidores de la interacción proteína-proteína keap1-nrf2
BR112022007720A2 (pt) Anticorpos humanizados para ligante 1a tnf-like (tl1a) e seus usos
MA41778A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
BR112018006135A2 (pt) derivados de pirazol fundidos como inibidores da cinase
WO2019209995A3 (en) Optimized anti-tl1a antibodies
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
BR112018071602A2 (pt) compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase
BR112022024505A2 (pt) Isoxazolidinas como inibidores de ripk1 e uso dos mesmos
BR112016029632A2 (pt) derivados heteroaromáticos bicíclicos fundidos como inibidores de cinase
EA202192488A1 (ru) Антитела против tsg-6 и их применения
CO2023011969A2 (es) Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos
BR112022018480A2 (pt) Moduladores de nlrp3
BR112018011656A2 (pt) derivados de hexahidropirzinotriazinona como inibidores de quinase